// App-Quantinova.ai

TPS2597 : First-in-human trial of microRNA cancer therapy with MRX34, a liposomal miR-34 mimic: Phase Ia expansion in patients with advanced solid tumors.

Researchers

Presenter

  • Muhammad Shaalan Beg

Principal Investigators

  • David S. Hong

  • Jasgit C. Sachdev

  • Andrew Jacob Brenner

  • Mitesh J. Borad

  • Ho Yeong Lim

  • Tae-You Kim

  • Carlos Becerra

  • Keunchil Park

  • Andreas G. Bader

  • Jay Stoudemire

  • Susan Smith

  • Sinil Kim

  • Yoon-Koo Kang

Medical Centers

  • Division of Hematology/Oncology, The University of Texas Southwestern Medical Center, Dallas, TX

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

  • Scottsdale Healthcare, Paradise Valley, AZ

  • University of Texas Health Science Center San Antonio, San Antonio, TX

  • Mayo Clinic, Scottsdale, AZ

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX

  • Mirna Therapeutics Inc, Austin, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Central Nervous System (CNS)

Disease

  • Solid malignancies

  • Lung Cancer

  • Melanoma

  • Mental retardation, X-linked 21

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • MRX34

Outcome

  • N/A

Study Design

  • Pharmacodynamics

  • Dose Escalation

  • First-In-Human

Phase

  • I

Study Id's

  • NCT01829971

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved